CMN Weekly (7 June 2024) - Your Weekly CRISPR...
CMN Weekly
Jun. 7, 2024
Disrupting the Care of Cardiovascular Disease With Single-Course Gene Editing Medicines | Wednesday September 6, 2023 | 2:00 pm–3:00 pm CEST / 8:00 am–9:00 am EDT
On-demand webinar is available - Follow this link
Disrupting the Care of Cardiovascular Disease With Single-Course Gene Editing Medicines
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programmess – VERVE-101 and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease, in order to durably reduce blood LDL-C levels.
VERVE-101 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat atherosclerotic cardiovascular disease (ASCVD) patients not at goal on oral therapy. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed in homozygous familial hypercholesterolemia (HoFH) and ultimately to treat patients with refractory hypercholesterolemia.
What will you learn from this webinar:
Atherosclerotic Cardiovascular Disease (ASCVD) unmet needs
Challenges of in vivo gene editing
Pre-clinical translation
Webinar Programme (CEST time zone):
- 14.00 Welcome and introduction by CRISPR Medicine News
- 14.05 Andrew Bellinger, M.D., Ph.D. |Disrupting the Care of Cardiovascular Disease With Single-Course Gene Editing Medicines
- 14.45 Q & A with Andrew Bellinger, M.D., Ph.D.
- 15.00 Close by CRISPR Medicine News
Speaker | Title:
Andrew Bellinger, M.D., Ph.D.
Chief Scientific Officer / Chief Medical Officer, Verve Therapeutics | Disrupting the Care of Cardiovascular Disease With Single-Course Gene Editing Medicines
Speakers
Andrew Bellinger, M.D., Ph.D. Chief Scientific Officer / Chief Medical Officer, Verve Therapeutics
Dr. Andrew Bellinger is the chief scientific and medical officer at Verve Therapeutics. He is a cardiologist and scientist who specialises in company creation and growth, building high-performing research and development teams, translational medicine, drug delivery, and has a particular interest in the clinical development of novel classes of therapies. Prior to joining Verve, Andrew co-founded and served as chief scientific officer of Lyndra Therapeutics, and prior to that he was the chief scientific officer of Cocoon Biotech. He is also a co-founder of Corner Therapeutics. He previously practiced as an attending cardiologist at Brigham and Women’s Hospital and is board-certified in cardiovascular medicine and internal medicine.
Andrew holds an M.D., a Ph.D., and an MPhil from Columbia University, an M.S. in mathematics from New York University, and an A.B. in physics from Princeton University. He completed his clinical training in internal medicine at the University of California, San Francisco, and his clinical training in cardiology at Brigham and Women’s Hospital. He completed his postdoctoral research training in drug delivery with Dr. Robert Langer at the Massachusetts Institute of Technology.
Read our CMN interview with Verve Therapeutics co-founder and CEO Sekar Kathiresan here.
CMN Articles - Verve Therapeutics
Familial Hypercholesterolemia, HeFH, or Premature Coronary Artery Disease, CAD, (NCT06164730)
Sponsors:
Verve Therapeutics, Inc.
Sponsors:
Verve Therapeutics, Inc.
IND Enabling
Phase I
Phase II
Phase III
